DO-BO

LEADING EMPLOYER 2025

We are proud to officially announce that MArS Market Access & Pricing Strategy has been recognized as one of the LEADING EMPLOYERS, ranking us within the top 1% of companies across Germany!

With flexibility, innovation and respect defining how we work together, this award reflects our strong company culture. Together we cultivate a thriving environment through: flexible working hours, digital coffee breaks & team bonding, a culture of trust, mutual respect and diversity as well as innovation-driven solutions, including AI-powered platforms. We believe that happy and empowered employees drive success!

It’s been an incredible journey for us, starting as a D-A-CH-focused consultancy to expanding globally with AI-driven training solutions – and this recognition motivates us to keep pushing boundaries in market access, pricing, and beyond. A huge thank you to our entire team – this award belongs to all of you!

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]